Contrast agents to combine 1H and 19F MRI

Today, magnetic resonance imaging (MRI) is based on the detection of water protons (1H) in tissues. MRI of 19F fluorine offers complementary advantages, but its use is hampered by a lack of suitable imaging agents, soluble in water and easily detectable. In order to improve the sensitivity of detecting 19F MRI signals, a CBM team used Mn2+ ions to form complexes with small fluorinated molecules. Unlike currently used nanoparticles, these small molecular probes have well-defined chemical structures and better biocompatibility and water solubility. Finally, thanks to the paramagnetism of manganese(II), they generate a strong signal in MRI. In addition, these fluorinated contrast agents are also active in proton MRI, allowing proton and fluorine MRI images to be superimposed for precise anatomical mapping.

This advance, published in Angewandte Chemie International Edition, opens new horizons in fluorine MRI. It was reported by CNRS Chimie on its website.

Reference :
Small, Fluorinated Mn2+ Chelate as an Efficient 1H and 19F MRI Probe
Éva Tóth, Zoltán Garda, Frédéric Szeremeta, Océane Quin, Enikő Molnár, Balázs Váradi, Rudy Clémençon, Sandra Même, Chantal Pichon and Gyula Tircsó
Angewandte Chemie International Edition, 2024
DOI: 10.1002/anie.202410998

2024 edition of “The Future of Molecular MR” international conference

The "Metal complexes and MRI" group of CBM is organizing the 2024 edition of "The Future of Molecular MR" meeting in Orléans which will gather 120 participants from over the world.

The objectives of this international conference are to establish current state of the art in molecular MR and pinpoint knowledge gaps, to identify adjacent technologies that can be combined with molecular MRI to create more accurate, ensitive, rapid and quantitative methods, and to bring leaders from different fields to challenge orthodoxy and identify new opportunities in molecular MR.

The meeting will take place in Hotel Dupanloup, Orléans, 17-20 June 2024.

Congress website

 

 

Breast cancer: towards early diagnosis by imaging

In vivo imaging of metastatic breast cancer tumors at very early stages is about to become possible. A team of chemists and biologists from the Center for Molecular Biophysics (CNRS) has indeed developed a new magnetic resonance imaging (MRI) probe which has a selective affinity for an emerging biomarker of metastatic breast cancer: Netrin- 1. Find out more on the Cnrs Chimie website.

See more and Cnrs Chmie website.

Reference
Peptide-Conjugated MRI Probe Targeted to Netrin-1, a Novel Metastatic Breast Cancer Biomarker
Clémentine Moreau, Tea Lukačević, Agnès Pallier, Julien Sobilo, Samia Aci-Sèche, Norbert Garnier, Sandra Même, Éva Tóth & Sara Lacerda
Bioconjugate Chemistry 2024
https://doi.org/10.1021/acs.bioconjchem.3c00558